Jupiter Wealth Management LLC Reduces Stock Position in Humana Inc (NYSE:HUM)

Jupiter Wealth Management LLC lessened its position in shares of Humana Inc (NYSE:HUM) by 0.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 19,258 shares of the insurance provider’s stock after selling 103 shares during the quarter. Humana accounts for 2.7% of Jupiter Wealth Management LLC’s portfolio, making the stock its 15th largest position. Jupiter Wealth Management LLC’s holdings in Humana were worth $5,430,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of HUM. Diamond Hill Capital Management Inc. purchased a new stake in Humana during the 2nd quarter valued at about $86,802,000. Ceredex Value Advisors LLC lifted its holdings in shares of Humana by 31.8% in the 1st quarter. Ceredex Value Advisors LLC now owns 957,094 shares of the insurance provider’s stock valued at $255,111,000 after buying an additional 230,671 shares during the period. BlackRock Inc. lifted its holdings in shares of Humana by 1.6% in the 1st quarter. BlackRock Inc. now owns 12,190,049 shares of the insurance provider’s stock valued at $3,242,553,000 after buying an additional 186,997 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Humana by 8.3% in the 4th quarter. Geode Capital Management LLC now owns 1,773,576 shares of the insurance provider’s stock valued at $507,198,000 after buying an additional 135,776 shares during the period. Finally, Janus Henderson Group PLC lifted its holdings in shares of Humana by 3.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,596,204 shares of the insurance provider’s stock valued at $956,594,000 after buying an additional 120,905 shares during the period. Institutional investors and hedge funds own 91.33% of the company’s stock.

Several equities analysts have recently issued reports on HUM shares. Citigroup decreased their price objective on Humana from $362.00 to $302.00 and set a “buy” rating for the company in a report on Thursday, May 2nd. SunTrust Banks boosted their price objective on Humana to $340.00 and gave the company a “hold” rating in a report on Thursday, August 1st. ValuEngine raised Humana from a “sell” rating to a “hold” rating in a report on Friday, July 12th. Oppenheimer decreased their price objective on Humana from $373.00 to $350.00 and set an “outperform” rating for the company in a report on Thursday, May 2nd. Finally, Piper Jaffray Companies boosted their price objective on Humana from $315.00 to $341.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have issued a buy rating to the company. Humana presently has an average rating of “Buy” and an average target price of $342.26.

NYSE HUM traded up $5.94 during trading hours on Friday, reaching $297.00. The company’s stock had a trading volume of 605,000 shares, compared to its average volume of 1,168,642. The firm has a market capitalization of $39.32 billion, a price-to-earnings ratio of 20.41, a P/E/G ratio of 1.26 and a beta of 0.85. Humana Inc has a 1-year low of $225.65 and a 1-year high of $355.88. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.75. The company’s 50-day moving average is $281.97 and its two-hundred day moving average is $271.56.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.05 earnings per share for the quarter, topping analysts’ consensus estimates of $5.24 by $0.81. The company had revenue of $16.25 billion during the quarter, compared to analysts’ expectations of $15.88 billion. Humana had a return on equity of 22.47% and a net margin of 4.13%. Humana’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.96 EPS. Equities analysts forecast that Humana Inc will post 17.63 EPS for the current fiscal year.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Story: What are the risks of holding treasury bonds?

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.